Drug-information
PFIZER AND BIONTECH VACCINE TO
COMBAT COVID-19
What is in the vaccine?
the Pfizer-BioNTech vaccine is based on the virus’s genetic instructions for
building the spike protein. The technology relies on a small piece of messenger
RNA (mRNA) from the coronavirus genome. It delivers a gene that codes for the
coronavirus'...
The German company BioNTech
partnered with Pfizer to develop and test a coronavirus vaccine known as
BNT162b2. The mRNA technology, short for messenger RNA vaccines like Pfizer's
are often referred to as the vaccines of the future, since the technology is
fairly new.
·
The active ingredient is messenger RN...
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S.
Food and Drug Administration (FDA) and the Moderna vaccine is soon to
follow, here’s a look at several of the top COVID-19 vaccine candidates
and where they stand as of today.
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 StudyVaccine
candidate was found to be more than 90% effective in preventing
COVID-19 in participants without evidence of prior SARS-CoV-2 infection
in the first interim efficacy analysisAnalysis evaluated 94 confirmed cases...
Bangladesh has entered into a deal with the Serum Institute of India (SII) to acquire 30 million doses of a potential vaccine being developed by AstraZeneca for Covid-19.SII and Bangladesh’s drugmaker Beximco Pharma signed a Memorandum of Understanding (MoU) for priority delivery of the vaccine doses.Under the deal, Beximco will purchase five milli...
Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens
appeared to have little or no effect on hospitalized COVID-19, as
indicated by overall mortality, initiation of ventilation and duration
of hospital stay. The mortality findings contain most of the randomized
evidence on Remdesivir and Interferon, and are consistent with
me...
In a paper on the interim findings on the four drugs, WHO's Solidarity
trial researchers in 30 countries return a clear negative.
The multi-country Solidarity trial
anchored by the World Health Organization (WHO) has concluded that none of the
four repurposed drugs that it examined — remdesivir, hydroxychloroquine (HCQ),...
Comparative study of PPI for symptom
relief in patients with reflux esophagitis:
Some of the present study demonstrated
that esomeprazole gave faster symptom relief than pantoprazole, lansoprazole
and omeprazole.
Because:
Esomeprazole has been shown to have a
faster onset of anti-secretory...
Comparative study of PPI for symptom
relief in patients with reflux esophagitis:
Some of the present study demonstrated
that esomeprazole gave faster symptom relief than pantoprazole, lansoprazole
and omeprazole.
Because:
Esomeprazole has been shown to have a
faster onset of anti-secretory...
Comparative study of PPI for symptom
relief in patients with reflux esophagitis:
Some of the present study demonstrated
that esomeprazole gave faster symptom relief than pantoprazole, lansoprazole
and omeprazole.
Because:
Esomeprazole has been shown to have a
faster onset of anti-secretory...
Usual Adult Dose for Fever
Oral:
Doses may be given as a single or repeated dose as follows:
Immediate-release: 325 mg to 1 g
orally every 4 to 6 hours
Minimum Dosing Interval: every 4
hoursMaximum Single Dose: 1000 mgMaximum Dose: 4 g/24 hours
Extended-Release: 1300 mg orally
every 8 hours
Maximum dose...
UMHS Lipid Therapy
Guideline Recommendations (2014)
The guidelines showed that Rosuvastatin
is the most potent statins with respect to lowering LDL, followed by
atorvastatin, pitavastatin, simvastatin and lovastatin.
Rosuvastatin 40 mg reducing LDL cholesterol by
63% whereas Atorvastatin 80...
